Novo Nordisk Unusual Options Activity For July 26
Novo Nordisk Unusual Options Activity For July 26
Investors with a lot of money to spend have taken a bearish stance on Novo Nordisk (NYSE:NVO).
擁有大量資金的投資者看跌挪威諾德斯克（紐交所：NVO）。
And retail traders should know.
零售交易者應該知道。
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
我們在這裏追蹤的公開期權歷史記錄上看到交易時發現了這一點。
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
無論這些機構是真的還是隻是富人，我們都不知道。但當一些大事發生在NVO，通常意味着有人知道即將發生的事情。
So how do we know what these investors just did?
那麼我們如何知道這些投資者剛剛做了什麼呢？
Today, Benzinga's options scanner spotted 21 uncommon options trades for Novo Nordisk.
今天，本辛加的期權掃描器發現了21次非常規期權交易，涉及挪威諾德斯克。
This isn't normal.
這不正常。
The overall sentiment of these big-money traders is split between 42% bullish and 52%, bearish.
這些大資金交易者的整體情緒分爲42％看漲和52％看淡。
Out of all of the special options we uncovered, 13 are puts, for a total amount of $538,028, and 8 are calls, for a total amount of $425,198.
在我們發現的所有特殊期權中，有13個看跌期權，交易總額爲538,028美元，有8個看漲期權，交易總額爲425,198美元。
Predicted Price Range
預測價格區間
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $175.0 for Novo Nordisk over the last 3 months.
根據這些合同的成交量和持倉量，似乎過去3個月中鯨魚一直將挪威諾德斯克的目標價位區間定在80.0到175.0美元之間。
Insights into Volume & Open Interest
成交量和持倉量分析
In today's trading context, the average open interest for options of Novo Nordisk stands at 1150.07, with a total volume reaching 5,185.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $80.0 to $175.0, throughout the last 30 days.
在今天的交易環境中，挪威諾德斯克期權的平均持倉量爲1150.07，總成交量達5185.00。附圖呈現了過去30天內挪威諾德斯克高價值交易看漲和看跌期權的成交量和持倉量進展情況，它們都定位於80.0到175.0美元的行權價走廊內。
Novo Nordisk Call and Put Volume: 30-Day Overview
挪威諾德斯克看漲和看跌成交量：30天概述
Largest Options Trades Observed:
觀察到的最大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | CALL | SWEEP | BULLISH | 08/09/24 | $4.05 | $4.0 | $4.05 | $129.00 | $104.0K | 522505 | |
| NVO | CALL | SWEEP | BULLISH | 11/15/24 | $5.55 | $5.4 | $5.5 | $140.00 | $82.3K | 457152 | |
| NVO | PUT | SWEEP | BEARISH | 01/16/26 | $15.2 | $15.1 | $15.2 | $125.00 | $75.8K | 72455 | |
| NVO | PUT | SWEEP | BEARISH | 08/16/24 | $1.28 | $1.27 | $1.27 | $115.00 | $63.5K | 8422.0K | |
| NVO | CALL | SWEEP | BULLISH | 11/15/24 | $11.85 | $11.75 | $11.85 | $125.00 | $53.3K | 1245 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | 看漲 | SWEEP | 看好 | 08/09/24 | $4.05 | $4.0 | $4.05 | $129.00 | 104,000美元 | 522505 | |
| NVO | 看漲 | SWEEP | 看好 | 11/15/24 | $5.55 | $5.4 | $5.5 | $140.00 | $82.3K | 457152 | |
| NVO | 看跌 | SWEEP | 看淡 | 01/16/26 | $15.2 | $15.1 | $15.2 | $125.00 | $75.8K | 72455 | |
| NVO | 看跌 | SWEEP | 看淡 | 08/16/24 | $1.28 | 1.27美元 | 1.27美元 | $115.00 | $63.5K | 8422.0K | |
| NVO | 看漲 | SWEEP | 看好 | 11/15/24 | 11.85美元 | 11.75美元 | 11.85美元 | $125.00 | 53.3千美元 | 1245 |
About Novo Nordisk
諾和諾德是一家領先的全球醫療保健公司，致力於研發創新藥品，幫助患糖尿病的患者過上更長壽、更健康的生活，這一傳統已有100多年。這種傳統爲我們提供了經驗和能力，使我們能夠推動變革，幫助人們戰勝其他嚴重的慢性疾病，如肥胖症、罕見的血液和內分泌紊亂。我們始終堅信，持久的成功公式是保持專注，長遠思考，並以財務、社會和環境負責任的方式做生意。諾和諾德在新澤西州設有美國總部，在7個州加上華盛頓特區擁有商業、生產和研究設施，在全國約有8000名員工。有關更多信息，訪問novonordisk-us.com，Facebook、Instagram和X。
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
作爲全球治療糖尿病品牌市場三分之一的領先者，丹麥的Novo Nordisk公司是世界上提供糖尿病護理產品的主要製造商和市場推廣者。該公司製造和銷售各種人體和現代胰島素、GLP-1療法等可注射糖尿病治療藥物、口服降糖藥以及肥胖症治療藥物。Novo Nordisk還有一個生物製藥部門（約佔營收的10%），專門從事血友病和其他疾病的蛋白質療法。
Following our analysis of the options activities associated with Novo Nordisk, we pivot to a closer look at the company's own performance.
在分析與挪威諾德斯克相關的期權活動之後，我們轉向更仔細地研究公司自身的表現。
Present Market Standing of Novo Nordisk
Novo Nordisk的現有市場地位
- Currently trading with a volume of 2,454,258, the NVO's price is down by -0.41%, now at $127.34.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 12 days.
- 目前交投量爲2,454,258的NVO股價下跌了-0.41％，現在是127.34美元。
- RSI讀數表明該股票目前可能接近超賣狀態。
- 預期收益將於 12 天內發佈。
Professional Analyst Ratings for Novo Nordisk
挪威諾德斯克的專業分析師評級
1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.
1位市場專家最近對該股進行了評級，達成了160.0美元的共識目標價。
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
- 來自Cantor Fitzgerald的分析師將其評級調降爲超配，目標價爲160美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。